To animate the Banner

Picture Name

Apply for post


Recruitment Position

Place of work

Number of Recruits

Salary Treatment

Obutiinib 2

Obitinib (trade name: Yinokai) is a highly selective new BTK inhibitor independently developed by Nuo Cheng Jianhua. Obitinib has an innovative compound structure, resulting in high selectivity, reduced off-target effects, and better efficacy and safety. The registered clinical trial of obutib for the first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has been completed and the new drug application (NDA) is expected to be submitted in 2024. CLL/SLL, one of the most common types of leukemia, is an indolent malignancy of B lymphocytes. Globally, there are 191000 new cases of CLL and 61000 deaths each year.

Gender
Marriage
kg
cm
Please upload a resume file smaller than 5M ~